COSENTYX is a PsO treatment proven effective for PsA
COSENTYX is a PsO treatment proven effective for PsA
In pivotal study FUTURE 2 in patients with active PsA
A majority of patients achieved
ACR 20 response at Week 24 (NRI)1*
(P<0.0001 for both Rx groups vs placebo)*
- COSENTYX 300 mg (n=100): 54%
- COSENTYX 150 mg (n=100): 51%
- Placebo (n=98): 15%
*Except where noted, patients received an initial once-weekly
x5 weeks loading
dose followed by doses every 4 weeks.1

†NBRx share for PsO/PsA/AS in rheumatology offices allocated using SHS PTD factors where RA (rheumatoid arthritis) is carved out for TNFs. NBRx is New to Brand measure showing the volume of NPA prescriptions associated with first-time use of a product. It reports prescriptions for patients who are starting therapy with a product for the first time, from March 2018 to February 2019.2
Click here to see study designs.
ACR=American College of Rheumatology; AS=ankylosing spondylitis; NPA=National Prescription Audit; NRI=nonresponder imputation; PsA=psoriatic arthritis; PsO=plaque psoriasis; PTD=Patient Transactional Data; TNF=tumor necrosis factor.
References: 1. McInnes IB, Mease PJ, Kirkham B, et al. for the FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146. 2. Data on file. IQVIA Step-by-step PsA share calculation. Novartis Pharmaceuticals Corp; March 2018 to February 2019. 3. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2018. 4. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890-897. 5. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423-441. 6. Data on file. CAIN457F2342 (FUTURE 5): Week 52 Interim Report. Novartis Pharmaceuticals Corp; August 2018. 7. Data on file. CAIN457F2342 Clinical Study Report Interim Analysis-Week 24. Novartis Pharmaceuticals Corp; November 2017.